<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00301093</url>
  </required_header>
  <id_info>
    <org_study_id>04-126</org_study_id>
    <secondary_id>R21CA115043</secondary_id>
    <secondary_id>P30CA006516</secondary_id>
    <secondary_id>CDR0000456445</secondary_id>
    <nct_id>NCT00301093</nct_id>
    <nct_alias>NCT00215475</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia</brief_title>
  <official_title>Vaccination for CML Patients With Persistent Disease on Imatinib Mesylate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from gene-modified cancer cells may help the body build an effective&#xD;
      immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells&#xD;
      by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with&#xD;
      imatinib mesylate may be an effective treatment for chronic myelogenous leukemia.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy&#xD;
      when given together with imatinib mesylate in treating patients with chronic phase chronic&#xD;
      myelogenous leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of GM-K562 cell vaccine when administered with&#xD;
           imatinib mesylate in patients with persistent chronic phase chronic myelogenous leukemia&#xD;
           in first hematologic response.&#xD;
&#xD;
        -  Determine the safety and toxic effects of GM-K562 cell vaccination in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the disease response by serial BCR-ABL quantitative polymerase chain reaction&#xD;
           measurements in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the development of tumor immunity in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of GM-K562.&#xD;
&#xD;
      Patients continue to receive oral imatinib mesylate at the same stable dose as before study&#xD;
      entry. Patients receive GM-K562 subcutaneously on days 1, 8, 15, 29, 43, 57, 85, 113, and 141&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 10 patients receive escalating doses of GM-K562 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 10 patients&#xD;
      experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 20 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">September 10, 2020</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the safety and toxicity of GM-K462 vaccination in CP CML patients who have acheived a complete hematologic response to imatinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Response</measure>
    <time_frame>3 years</time_frame>
    <description>To assess disease response after GM-K562 vaccination by serial BCR-ABL Q-PCR measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor immunity</measure>
    <time_frame>3 years</time_frame>
    <description>To characterize the development of tumor immunity in response to vaccination with GM-K562 cells</description>
  </secondary_outcome>
  <enrollment type="Actual">3</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GM-K562 cell vaccine</intervention_name>
    <description>Once weekly for 3 vaccination, then every other week for 3 vaccinations, and then every month for 3 vaccinations until the participant has received a total of 9 vaccinations</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Participants will continue on current dose</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of chronic myelogenous leukemia&#xD;
&#xD;
               -  Chronic phase disease&#xD;
&#xD;
               -  Philadelphia chromosome positive disease&#xD;
&#xD;
          -  Disease in first complete hematologic response, defined by all of the following:&#xD;
&#xD;
               -  Complete normalization of peripheral blood counts with WBC &lt; 10,000/mm^3&#xD;
&#xD;
               -  Platelet count &lt; 450,000/mm^3&#xD;
&#xD;
               -  No immature cells (e.g., myelocytes, metamyelocytes, or blasts) in the peripheral&#xD;
                  blood&#xD;
&#xD;
          -  Persistent molecular evidence of disease&#xD;
&#xD;
               -  Detectable BCR-ABL transcript by quantitative polymerase chain reaction&#xD;
&#xD;
               -  Less than 2 log reduction in peripheral blood or bone marrow BCR-ABL transcripts&#xD;
                  levels compared to a standardized baseline&#xD;
&#xD;
          -  Must have received imatinib mesylate for &gt; 1 year of which the last 3 months were at&#xD;
             stable dose ≥ 300 mg/day&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No known HIV&#xD;
&#xD;
          -  ALT or AST ≤ 3 times upper limit of normal&#xD;
&#xD;
          -  Oxygen saturation ≥ 93% at room air&#xD;
&#xD;
          -  No history of recent acute myocardial infarction&#xD;
&#xD;
          -  No history of unstable angina&#xD;
&#xD;
          -  No pulmonary decomposition requiring hospitalization within the past 3 months&#xD;
&#xD;
          -  No concurrent and/or uncontrolled psychiatric or medical condition that would preclude&#xD;
             study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  At least 2 months since other prior experimental therapy&#xD;
&#xD;
          -  At least 6 months since prior participation in another vaccine study&#xD;
&#xD;
          -  No concurrent systemic immunosuppressive medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martha Wadleigh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 8, 2006</study_first_submitted>
  <study_first_submitted_qc>March 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2006</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Martha Wadleigh, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

